# Phase II Iressa Versus Vinorelbine (INVITE)

> **NCT00256711** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 192 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT00256711
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 192 (—)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256711, "Phase II Iressa Versus Vinorelbine (INVITE)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00256711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*